AnteoTech (ASX:AD) share price surges 15% as COVID-19 RAT race continues

The scientific company's shares have bounced back after a horror start to the week.

| More on:
a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The AnteoTech share price shot 15% higher today
  • It follows media speculation RATs not approved by the TGA may be imported into Australia
  • Yesterday, the company's shares fell 13%

The AnteoTech Ltd (ASX: ADO) share price surged today in a massive turnaround from its plummet yesterday.

The scientific research company's shares finished the day at 22.5 cents, a 15.38% gain. In contrast, the S&P/ASX 200 Index (ASX: XJO) closed up 0.49% today.

Let's take a look at what might have impacted the AnteoTech share price today.

What's happening at AnteoTech?

AnteoTech has developed a COVID-19 rapid antigen test (RAT) for its EuGeni Reader diagnostic platform. However, the company is still awaiting approval from the Therapeutic Goods Administration for its use in Australia.

Now speculation is mounting that RATs not currently approved by the TGA could be allowed into Australia.

The Guardian reported today the federal government has "quietly agreed" to allow unapproved rapid antigen tests into the country for personal use.

AnteoTech's share price has surged today after a 13% fall yesterday.

As my Foolish colleague Aaron reported, the company is continuing to engage with the TGA on regulatory approval for its RAT test. AnteoTech also received $1.96 million from the federal government's Research and Development tax incentive scheme.

The regulator has asked the company to supply more clinical data. Chief executive officer Derek Thomson said:

The TGA has advised us we must add prospective clinical data to support our test performance claims generated using stored samples to align our technical data with the [Medical Device Coordination Group] MDCG guidelines.

We are currently collecting this data via trials in Australia and Europe, which will also provide the required data set for entry to the EU Common List and [In Vitro Diagnostic Regulation] IVDR registration.

The company's application for TGA approval was submitted in September. The Australian reported that although the RATS are not approved for use in Australia, they are made in Eight Miles Plains in Queensland and shipped offshore.

Meanwhile, federal opposition leader Anthony Albanese pledged on Sunday to prioritise locally-manufactured RAT tests if elected, The Canberra Times reported.

Share price snapshot

The AnteoTech share price has skyrocketed 125% in the past year. However, it's dropped around 26% in the past month and is down 39% in the past week alone.

In contrast, the broader ASX 200 Index has returned about 5% in the past 52 weeks.

AnteoTech has a market capitalisation of $444 million based on its current share price.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 10% on big news

This stock is catching the eye with a strong gain on Thursday. But why?

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »